GlaxoSmithKline  and Alnylam Pharmaceuticals  recently announced that BIO Ventures for Global Health  will administer the Intellectual Property (IP) Pool to aid in the discovery and development of new treatments for neglected tropical diseases.
Lila Feisee, Managing Director for Intellectual Property at BIO, hosted a discussion on the IP pool with:
The participants explained how the IP pool will provide patents as well as access to technologies and the individuals who did the work which resulted in the patents. This will help researchers decide on the best course of action in order to pursue new medicines to treat neglected tropical diseases. This sharing of collective knowledge will advance research and possibly speed the development of treatments for patients in developing nations.
You can learn more about the IP pool established by GlaxoSmithKline and Alnylam at http://www.gsk.com/collaborations/patentpool.htm .